Rockwell Medical, Inc. (RMTI)
| Market Cap | 35.07M |
| Revenue (ttm) | 69.26M |
| Net Income (ttm) | -5.47M |
| Shares Out | 39.41M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,934 |
| Open | 0.846 |
| Previous Close | 0.846 |
| Day's Range | 0.841 - 0.890 |
| 52-Week Range | 0.780 - 2.100 |
| Beta | 1.71 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+124.72%) |
| Earnings Date | May 7, 2026 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic a... [Read more]
Financial Performance
In 2025, Rockwell Medical's revenue was $69.26 million, a decrease of -31.76% compared to the previous year's $101.49 million. Losses were -$5.47 million, 599.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for RMTI stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026.
Rockwell Medical Earnings Call Transcript: Q4 2025
Profitability was maintained on an adjusted EBITDA basis in 2025, with gross margin reaching historic highs in Q4 and a strengthened cash position. Expanded customer agreements and rapid response to supply chain disruptions drove growth, with 2026 guidance projecting further profitability.
Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.
Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026.
Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical has been certified as a Great Place to Work for the fourth year in a row.
Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--$RMTI announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025.
Rockwell Medical Adds 30 New Customers in the West
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is a viable alternative supplier in the western U.S., serving customers with a reliable supply chain and high-quality p...
Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical extends its product purchase agreement with one of the largest dialysis providers in the United States through December...
Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Joe Dawson is a seasoned executive who has extensive operational experience and a strong network in the renal care space.
Rockwell Medical Earnings Call Transcript: Q3 2025
Q3 2025 saw stable sequential sales but a 44% year-over-year decline due to a major customer transition, with gross margin stabilizing and adjusted EBITDA turning positive. Diversification, new contracts, and a strengthened cash position support growth and margin improvement into 2026.
Rockwell Medical Announces Third Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the third quarter 2025.
Rockwell Medical Names Rashad Brown Vice President, Manufacturing and Supply Chain
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Mr. Brown has built a distinguished career leading complex manufacturing and supply chain organizations.
Rockwell Medical to Exhibit at ASN Kidney Week 2025
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #316 at ASN Kidney Week 2025 in Houston, TX.
Rockwell Medical Named Fortune 'Best Workplaces in Manufacturing & Production' Second Year in a Row
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Our team's hard work and dedication are what make Rockwell Medical a leader in our industry and an exceptional place to build a career.
Rockwell Medical to Release Third Quarter 2025 Results on Wednesday, November 12, 2025
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025.
Rockwell Medical Promotes Heather Hunter to Chief Operating Officer
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Heather Hunter was promoted to Chief Operating Officer, having previously served as Chief Corporate Affairs Officer since August 2022.
Rockwell Medical Earnings Call Transcript: Q2 2025
Q2 2025 saw a 38% revenue decline due to the largest customer transition, but gross margin held steady at 16% and cash flow from operations was positive. Over 80% of customers are now under long-term contracts, reducing concentration risk and positioning for future growth.
Rockwell Medical Announces Second Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces financial and operational results for the three and six months ended June 30, 2025.
Rockwell Medical to Release Second Quarter 2025 Results on Thursday, August 14, 2025
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025.
Rockwell Medical and Innovative Renal Care Announce Three-Year Partnership Agreement to Ensure Supply Chain Continuity of Quality Hemodialysis Products
WIXOM, Mich. & FRANKLIN, Tenn.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply Innovative Renal Care with high-quality hemodialysis products to streamline workflows and...
Rockwell Medical Earnings Call Transcript: Q1 2025
Q1 2025 saw a 17% revenue decline due to a major customer transition, but gross margin improved to 16%. Guidance for 2025 is reaffirmed, with new product launches and expansion in Latin America and the U.S. West Coast expected to drive future growth.
Rockwell Medical Announces First Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces financial and operational results for the three months ended March 31, 2025.
Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2025 on Monday, May 12, 2025.
Rockwell Medical Earnings Call Transcript: Q4 2024
Net sales grew 21% to $101.5 million in 2024, with gross margin improving to 17% and adjusted EBITDA turning positive. 2025 is expected to be a transition year due to the loss of the largest customer, but guidance targets $65–$70 million in sales and continued profitability efforts.
Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history.